Tag:
Roger Bate
Latest Headlines
Latest Headlines
Google AdWords ban keeps drug savings from U.S. poor
The recent prohibition of Google ( $GOOG ) to sell AdWords to foreign online pharmacies, which follows its $500 million fine last month for doing so, hurts more than just Google's financials. It also
Price overlap blurs quality between generic, substandard drugs
Healthcare policies favoring low-cost generic drugs over innovators must also require closer regulation of the copycat meds and their manufacturing processes, or some other means of improving
One man's foreign-source warning is another's generics bash
"Most unfortunate" is what Roger Bate says of the headline of his opinion piece in last week's Wall Street Journal--"Beware the Risks of Generic Drugs"--because the article "really wasn't about
Chinese chemical inconsistency yields drug 'caveat emptor'
"Most Chinese chemicals are high quality, but poor oversight, weak regulation, and occasional grotesque negligence will likely compromise drug quality," says Roger Bate of the American Enterprise
Study finds fuzzy price/drug-quality link
Fifteen percent of 900 drug samples from developing countries failed at least one quality test and are priced 13 to 18 percent lower than non-failing drugs. The poor-quality/low-price link is as of
